Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
about
Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virusTherapeutic implications of hepatitis C virus resistance to antiviral drugs.Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan.Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
P2860
Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Interferon and ribavirin thera ...... hepatitis C virus polymerase.
@en
Interferon and ribavirin thera ...... hepatitis C virus polymerase.
@nl
type
label
Interferon and ribavirin thera ...... hepatitis C virus polymerase.
@en
Interferon and ribavirin thera ...... hepatitis C virus polymerase.
@nl
prefLabel
Interferon and ribavirin thera ...... hepatitis C virus polymerase.
@en
Interferon and ribavirin thera ...... hepatitis C virus polymerase.
@nl
P2093
P1476
Interferon and ribavirin thera ...... n hepatitis C virus polymerase
@en
P2093
P304
P356
10.1111/J.1365-2893.2008.00980.X
P577
2008-03-24T00:00:00Z